U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H34N4O2
Molecular Weight 482.6166
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALECTINIB

SMILES

CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6

InChI

InChIKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N
InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C30H34N4O2
Molecular Weight 482.6166
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Alectinib is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. Alectinib is marketed as Alecensa.

CNS Activity

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Alecensa
PubMed

PubMed

TitleDatePubMed
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
2014 Nov 15
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
2014 Nov 15
Patents

Patents

Sample Use Guides

In Vivo Use Guide
600 mg orally twice daily. Administer with food.
Route of Administration: Oral
In Vitro Use Guide
Alectinib exhibited antiproliferative activity against SNU-2535 cells in vitro with IC50 of 33.1 nM.
Substance Class Chemical
Created
by admin
on Mon Oct 21 21:34:41 UTC 2019
Edited
by admin
on Mon Oct 21 21:34:41 UTC 2019
Record UNII
LIJ4CT1Z3Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALECTINIB
DASH   INN   USAN   WHO-DD  
USAN   INN  
Official Name English
ALECTINIB [INN]
Common Name English
AF-802
Code English
ALECTINIB [WHO-DD]
Common Name English
RO-5424802
Code English
9-ETHYL-6,6-DIMETHYL-8-(4-(MORPHOLIN-4-YL)PIPERIDIN-1-YL)-11-OXO-6,11-DIHYDRO-5H-BENZO(B)CARBAZOLE-3-CARBONITRILE
Systematic Name English
ALECTINIB [USAN]
Common Name English
CH5424802
Code English
AF802
Code English
RO5424802
Code English
5H-BENZO(B)CARBAZOLE-3-CARBONITRILE, 9-ETHYL-6,11-DIHYDRO-6,6-DIMETHYL-8-(4-(4-MORPHOLINYL)-1-PIPERIDINYL)-11-OXO-
Systematic Name English
CH-5424802
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 462814
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
WHO-ATC L01XE36
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
NDF-RT N0000175605
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
NCI_THESAURUS C129825
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
NCI_THESAURUS C141136
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
Code System Code Type Description
EVMPD
SUB178557
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
IUPHAR
7739
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
PUBCHEM
49806720
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
RXCUI
1727455
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY RxNorm
ChEMBL
CHEMBL1738797
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
INN
9699
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
DRUG BANK
DB11363
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
EPA CompTox
1256580-46-7
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
LactMed
1256580-46-7
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
NCI_THESAURUS
C101790
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
NDF-RT
N0000175082
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY Kinase Inhibitors [MoA]
CAS
1256580-46-7
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
WIKIPEDIA
Alectinib
Created by admin on Mon Oct 21 21:34:41 UTC 2019 , Edited by admin on Mon Oct 21 21:34:41 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
IC50
EXCRETED UNCHANGED
Alectinib was not detected in urine.
URINE
EXCRETED UNCHANGED
In feces, alectinib accounted for 84% of the cumulative excretion of the radioactivity within 168 hours. The relatively high percentage of unchanged alectinib in the feces is consistent with relatively low solubility compared to the estimated concentration of alectinib in the stomach following a dose of 600 mg
FECAL
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC FED CONDITION

SINGLE DOSE